Jane Huang - 31 Aug 2021 Form 4 Insider Report for BeiGene, Ltd. (ONC)

Role
CMO, Hematology
Signature
/s/ Qing Nian, as Attorney-in-Fact
Issuer symbol
ONC
Transactions as of
31 Aug 2021
Net transactions value
-$346,621
Form type
4
Filing time
02 Sep 2021, 20:39:22 UTC
Previous filing
19 Jul 2021
Next filing
15 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BGNE Ordinary Shares Award $0 +7,163 +2.4% $0.000000 305,824 31 Aug 2021 Direct F1
transaction BGNE Ordinary Shares Award $0 +7,124 +2.3% $0.000000 312,948 01 Sep 2021 Direct F1
transaction BGNE American Depositary Shares Award $0 +542 $0.000000 542 31 Aug 2021 Direct F1, F2
transaction BGNE American Depositary Shares Sale $168,307 -542 -100% $310.53 0 01 Sep 2021 Direct F2, F3
transaction BGNE American Depositary Shares Award $0 +545 $0.000000 545 01 Sep 2021 Direct F1, F2
transaction BGNE American Depositary Shares Sale $178,314 -545 -100% $327.18 0 02 Sep 2021 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting of a portion of a performance-based restricted share unit award upon satisfaction of performance conditions.
F2 Each American Depositary Share represents 13 Ordinary Shares.
F3 The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a performance-based restricted share unit award previously granted to the Reporting Person.